Regeneneron报告说,尽管投资者持有混合股票,但Q4的收益很高,超过估计数。 Regeneron reports strong Q4 earnings, exceeding estimates, despite mixed stock holdings by investors.

机构投资者阿根廷信托公司将Regeneron制药公司持有的股份减少了197股,降为2 192股,价值156万美元。 Institutional investor Argent Trust Co reduced its holdings in Regeneron Pharmaceuticals by 197 shares, down to 2,192 shares, worth $1.56 million. 与此同时,菲尼克斯金融有限公司的股份增加了336股。 Meanwhile, Phoenix Financial Ltd increased its holdings by 336 shares. 尽管投资活动好坏参半,Regeneron报告Q4收入强劲,每股12.07美元,超过分析师估计的0.86美元,收入逐年增加10.3%。 Despite the mixed investment activities, Regeneron reported strong Q4 earnings of $12.07 per share, exceeding analyst estimates by $0.86, with a 10.3% revenue increase year-over-year. 该公司以其治疗眼疾的EYLEA注射而著称,其市场上限为597.3亿美元。 The company, known for its EYLEA injection for treating eye conditions, has a market cap of $59.73 billion.